Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Speyeder999on May 15, 2024 3:18pm
75 Views
Post# 36041779

RE:RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

RE:RE:New Press Release - ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsI'm going with sooner than later.

With the company's current burn rate and 2,5M in cash and equivalents as of March 31, they'll run out of funds anytime now, if it hasn't happened already. Maybe in time for the AGF meeting so they can discuss the matter? Or not.....

I somehow recall last years AGF meeting took place at the end of June, stock was hovering around 4$-6$ for YEARS and roughly 2 weeks after, stock tumbles 60% (for a period of what seemed like 10 minutes)  and by some miracle, that's the timing management decides perform a financing (1.88$/share). Funny how this timing worked out perfectly so as management didn't have to adress this awkward issue as well as a 14M share one-day trading session at the AGM. 

So, a financing at 2$ ?, I'll believe it when I see it. I definitely want to average down before the Phase 1a news comes out, but at the same time, last years debacle has me believing the financing will occur well below1.88$ (JMO)
<< Previous
Bullboard Posts
Next >>